|
C2ORF44 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
6.28730401075472E-11 |
| Normal-vs-Stage3 |
3.33066907387547E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
6.189200E-01 |
| Stage1-vs-Stage3 |
2.245200E-01 |
| Stage1-vs-Stage4 |
8.389400E-04 |
| Stage2-vs-Stage3 |
2.266400E-01 |
| Stage2-vs-Stage4 |
1.841500E-03 |
| Stage3-vs-Stage4 |
4.240100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
5.07550002026846E-09 |
| Normal-vs-Asian |
2.73229994185442E-10 |
| Caucasian-vs-AfricanAmerican |
8.001400E-01 |
| Caucasian-vs-Asian |
1.779640E-01 |
| AfricanAmerican-vs-Asian |
2.965200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
8.858200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
2.01105798680601E-12 |
| Normal-vs-Age(81-100Yrs) |
3.52829999999971E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.087200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.511600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.250800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.009000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.892600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.533000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.081800E-03 |
| Classical-VS-Follicular |
7.897700E-02 |
| Classical-VS-Other |
3.871000E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
4.039000E-04 |
| Tall-VS-Other |
5.166000E-01 |
| Tall-VS-Normal |
1.62458935193399E-12 |
| Follicular-VS-Other |
1.930360E-01 |
| Follicular-VS-Normal |
1.62340141329764E-11 |
| Other-VS-Normal |
4.06280000000425E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.260200E-03 |
|
|
